- By insider

CEO of Beigene Ltd (BGNE) John Oyler sold 99,000 shares of BGNE on 03/02/2018 at an average price of $145.63 a share. The total sale was $14.4 million.

BeiGene Ltd is a clinical-stage biopharmaceutical company engaged in the discovery & development of molecularly targeted & immuno-oncology drugs for the treatment of cancer. Its product includes BGB-3111, BGB-283 and BGB-290 and one immuno-oncology agent. BeiGene Ltd has a market cap of $6.85 billion; its shares were traded at around $150.72 with and P/S ratio of 29.18.

• Warning! GuruFocus has detected 3 Warning Signs with BGNE. Click here to check it out.

• BGNE 15-Year Financial Data

• The intrinsic value of BGNE

• Peter Lynch Chart of BGNE

CEO Recent Trades:

• CEO, 10% Owner John Oyler sold 99,000 shares of BGNE stock on 03/02/2018 at the average price of $145.63. The price of the stock has increased by 3.5% since.

Directors and Officers Recent Trades:

• EVP and Gl. Head of Bus. Dev. Ji Li sold 10,000 shares of BGNE stock on 02/28/2018 at the average price of $146.88. The price of the stock has increased by 2.61% since.

For the complete insider trading history of BGNE, click here

.This article first appeared on GuruFocus.

• Warning! GuruFocus has detected 3 Warning Signs with BGNE. Click here to check it out.

• BGNE 15-Year Financial Data

• The intrinsic value of BGNE

• Peter Lynch Chart of BGNE